403. Can BioTech Extend Life to 150 Years? Gene Editing, and Investing in the Future of Life Sciences (Risa Stack)

480. The OG Seed Investor, Mike Maples Jr., on Spotting Inflection Points, Living in the Future, and Why the Best Form of Competition Is No Competition (Mike Maples)

Investor Stories 398: Disruptive Forces (Ralston and Patil, Schilling, Stevens)

479. Inside the LP Playbook with Venture Vanguard, Chris Rizik: What Metrics Actually Matter, How to Fix Venture’s Liquidity Crisis, and Why Co-Invests Are a Trap (Chris Rizik)

Investor Stories 397: Key Advice (Ho, Yunger, Tusk)

478. Classical vs. Jazz Leadership, IPO Readiness & Key Metrics for a Successful Offering, Requirements for David to Beat Goliath, and Why Altman and Other Leaders are Pivoting to Open Source (Somesh Dash)

Investor Stories 396: Visionary Founders (Chau, Whitmire, Garcia)

477. The Biggest Misconceptions About AI Agents, Why Defensibility Doesn’t Matter at Seed, and Whether the AI Center of Gravity Is Shifting to China (Aaref Hilaly)

Investor Stories 395: Best LP Question (Upham, Ho, Yunger)

DNA als Plattform der Zukunft

Curing disease with CRISPR with Trevor Martin from Mammoth Biosciences

Trevor Martin (Mammoth Biosciences) and Ursheet Parikh (Mayfield) - Building Biotech to Last

Trailblazing discoveries in Gene Editing Solutions

Startup Insider Daily • Tesla-Hack • Insolvenzantragspflicht • Ripple • Basecamp-Exodus • CRISPR • Netflix

E42: China's tech crackdown, CRISPR breakthrough, practical climate change solutions & more

CRISPR/Cas9 mit Myopax

Startup Insider Daily • Recap • Fynn Kliemann • CRISPR • Turing-Test • Onecoin • Google Maps • Tesla • Apple • Ororatech